Company / EPS (Basic)
Lineage Cell Therapeutics, Inc. EPS (Basic) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
-$0.09
FY2025
5-year range
-$0.26 / -$0.01
FY2021-FY2025
Trend
+25.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Basic) has increased for 3 consecutive years, from $-0.26 in FY2022 to $-0.09 in FY2025.
Based on SEC 10-K filings.
-0.09 in FY2025.
Improved from $-0.15 to $-0.09 over the past 2 years.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Lineage Cell Therapeutics, Inc.'s eps (basic) has grown for 3 consecutive years.
- In FY2025, eps (basic) increased 25.0% year-over-year.
- Peak eps (basic) was recorded in FY2019.
- Lowest eps (basic) in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.09 | +25.0% |
| FY2024 | -$0.12 | +20.0% |
| FY2023 | -$0.15 | +42.3% |
| FY2022 | -$0.26 | -2500.0% |
| FY2021 | -$0.01 | +83.3% |
| FY2020 | -$0.06 | -120.0% |
| FY2019 | $0.30 | +160.0% |
| FY2018 | -$0.50 | +15.3% |
| FY2017 | -$0.59 | -7.3% |
| FY2016 | -$0.55 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026